Zurueck zur Suche

Reporte zur Charge UJ768AC

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

11Reporte angezeigt
0Todesfaelle
1Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
MI 2 NH 1 OH 1 TX 1 AR 1 MN 1 KS 1 ID 1 GA 1 IA 1

VAERS 2454588

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UJ768AC

moderat
Staat
MI
Alter
75,0
Geschlecht
F
Eingang
22.09.2022
Impfdatum
11.10.2021
Beginn
14.09.2022
Tage bis Beginn
338,0
Dosis
N/A
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: ja Disable: unbekannt ER: unbekannt Erholt: ja
Brain natriuretic peptide increased COVID-19 COVID-19 pneumonia Cardiomegaly Chest X-ray abnormal Cough Dyspnoea Echocardiogram Ejection fraction normal End stage renal disease Hypoxia Lung carcinoma cell type unspecified stage 0 Oropharyngeal pain Pulmonary congestion Wall motion score index abnormal

Symptomtext

Discharge Provider: MD Primary Care Provider: MD Admission Date: 9/14/2022 Discharge Date: Sep 20, 2022 PRESENTING PROBLEM: ESRD (end stage renal disease) (HCC) Pulmonary vascular congestion Malignant neoplasm of lung, unspecified laterality, unspecified part of lung (HCC) COVID-19 virus infection HOSPITAL COURSE: Patient 76-year-old female with her significant past medical history for stage IV lung cancer, history of breast cancer, chronic diastolic heart failure, CKD stage 4 with planning for fistula in future, presented to the hospital with multiple days of cough, dyspnea, sore throat since 9/12 found to have hypoxia with acute COVID-19 pneumonia. CXR with Mild cardiomegaly and vascular congestion without overt pulmonary edema. BNP elevated and TTE with small new WMA but LVEF normal and no signs of acute new CHF. Patient was not in any acute respiratory distress but needed 2 L of oxygen and was high risk so was admitted. Patient started on both dexamethasone and remedesivir along with supportive care. Improved to room air and remained stable. Plan discharge home with close follow up with both Oncology and Nephrology as well as PCP to consider repeat echo after resolution of covid infection. The patient was educated on need for close followup with PCP and nephrology with repeat labs in 1-2 weeks as her torsemide dose was decreased from BID to daily due to her renal function while inpatient.

Weitere VAERSDATA-Felder
Praegender Schweregrund
COVID-19 pneumonia
Hospital-Tage
6,0
Labordaten
-
Aktuelle Erkrankungen
10/4/2021 Urgent Care Leg Swelling Change of Skin Color
Vorgeschichte
Calculus of kidney Chronic gastric ulcer without hemorrhage or perforation Arthropathy Stage IV squamous cell carcinoma of lung (HCC) Major depressive disorder with single episode, in partial remission (HCC) Premature atrial complexes Bilateral lower extremity edema Stage IV squamous cell carcinoma of lung Essential hypertension Coronary artery calcification seen on CT scan Stage 4 chronic kidney disease Obesity (BMI 30-39.9) Acute renal failure (ARF) (HCC) History of left breast cancer Colitis At risk for adverse drug interaction Edema, unspecified type New daily persistent headache Laceration of left lower extremity, subsequent encounter Acute bronchitis due to other specified organisms Epigastric pain and heartburn Encounter for antineoplastic immunotherapy Drug-induced thyroiditis Balance problems Closed displaced fracture of medial condyle of right femur with routine healing Adjustment disorder with mixed emotional features Chronic anemia Other and unspecified coagulation defects Frequent UTI Esophageal reflux History of nephrolithiasis Hyperparathyroidism (HCC) Hypothyroidism Malignant neoplasm of upper lobe, bronchus, or lung Other abnormal glucose Secondary malignant neoplasm of liver (HCC) Other malaise and fatigue Shortness of breath Urinary tract infection Benign essential tremor Restless leg syndrome Chronic bilateral low back pain with sciatica Primary insomnia Pruritus Chronic pain Lymphedema Cellulitis Cat bite of forearm, right, initial encounter Hypoxia Breast cancer (HCC) COVID-19 virus infection
Andere Medikamente
acetaminophen (TYLENOL) 500 MG tablet aluminum, magnesium & simethicone (MAALOX EX) 400-400-40 MG/5ML budesonide (ENTOCORT EC) 3 MG delayed release capsule calcitriol (ROCALTROL) 0.25 MCG capsule cyclobenzaprine (FLEXERIL) 5 MG tablet diphe
Allergien
Iv ContrastHives ClonidineRash Penicillins Sulfa DrugsRash
Vorherige Impfungen
-

VAERS 1837155

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UJ768AC

mild
Staat
NH
Alter
66,0
Geschlecht
F
Eingang
06.11.2021
Impfdatum
18.10.2021
Beginn
19.10.2021
Tage bis Beginn
1,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Arthralgia Product administered at inappropriate site Axillary pain Back pain Pain in extremity

Symptomtext

pain in the arm ,under armpit and some upper back. Per patient her symptoms started 36 hours after vaccination, Patient had taken Tylenol with codeine on her own . Then ibuprofen alternating with tylenol per MD with not much result. She just was prescribed Naproxen and cyclobenzaprine and massage or physical therpay. outcome is unkown since medications were just prescribed.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Arthralgia
Hospital-Tage
-
Labordaten
unkown
Aktuelle Erkrankungen
unkown
Vorgeschichte
unkownn
Andere Medikamente
unkown
Allergien
unkown
Vorherige Impfungen
-

VAERS 1842351

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UJ768AC

mild
Staat
OH
Alter
68,0
Geschlecht
F
Eingang
04.11.2021
Impfdatum
-
Beginn
27.10.2021
Tage bis Beginn
-
Dosis
UNK
Route/Site
OT / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Injection site extravasation Pain in extremity Underdose Vaccination site pain

Symptomtext

her arm hurt; Patient was injected they noticed some of the liquid running down her arm to her wrist; Initial information received on 27-Oct-2021 regarding an unsolicited valid non-serious case received from a pharmacist via Media Information (under the reference 00831417). This case involves a 68 years old female patient whose arm hurt (vaccination site pain) and was injected they noticed some of the liquid running down her arm to her wrist (injection site extravasation) after receiving INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT]. The patient's medical history, medical treatment(s), vaccination(s) and family history were not provided. Patient had no other concomitant vaccines. On an unknown date, the patient received a dose of suspect FLUZONE HIGH-DOSE QUADRIVALENT (once, 0.25 mL to 2 mL, total, lot UJ768AC and expiration date: 30-Jun-2021) via intramuscular route in the left deltoid for prophylactic vaccination. On 27-Oct-2021, the patient developed a non-serious arm hurt (vaccination site pain) and was injected they noticed some of the liquid running down her arm to her wrist (injection site extravasation) (unknown latency) following the administration of vaccine. No laboratory data reported. It was reported "Caller stated that she was administering vaccine to patient, there was either a failure on the syringe portion or the needle portion and when pushing plunger in, some of the liquid came out and was running down the patient's arm. the needle was placed on the syringe tightly and there was no problem when the air was pushed out of the syringe nor did she hear any sound like a leak but when the consumer was injected they noticed it running down her arm to her wrist and she states her arm hurt. Pharmacist would like a credit and gets it from VAXSERVE." It was not reported if the patient received a corrective treatment. At time of reporting, the outcome was unknown for the reported events.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site extravasation
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1828909

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UJ768AC

mild
Staat
TX
Alter
66,0
Geschlecht
F
Eingang
29.10.2021
Impfdatum
29.10.2021
Beginn
29.10.2021
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Erythema Peripheral swelling Pruritus Skin warm

Symptomtext

Injection was given and within 10 minutes patient's arm was swollen, red, hot, and very itchy. Patient was given 25mg of IM Benadryl.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Pruritus
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
None documented in medical record through 3 months prior.
Vorgeschichte
Essential Hypertension, Irritable Bowel Syndrome, Acquired Hypothyroidism, Stage 3A Chronic Kidney Disease, Symptomatic Menopausal or Female Climacteric States, Malaise of Fatigue, Mass of Right Thigh, Mixed Hyperlipidemia, Morbid Obesity, Major Depressive Disorder.
Andere Medikamente
felodipine 5mg daily fluticasone propionate 100mcg/actuaction DsDz twice daily gabapentin 100mg 1-3 tablets three times daily levothyroxine 150mcg tablet daily Montelukast 10mg daily omeprazole 40mg daily simvastatin 40mg nightly **Given Be
Allergien
No known drug or food allergies
Vorherige Impfungen
-

VAERS 1794803

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UJ768AC

mild
Staat
AR
Alter
67,0
Geschlecht
F
Eingang
18.10.2021
Impfdatum
15.10.2021
Beginn
15.10.2021
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Rash erythematous Swelling

Symptomtext

Patient developed 4-6 inch approx. erythematous rash within 2 hours of vaccination. Swelling was significant. Symptoms persisted to 72 hours.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Rash erythematous
Hospital-Tage
-
Labordaten
None
Aktuelle Erkrankungen
None
Vorgeschichte
None
Andere Medikamente
Synthroid, Glaucoma Meds
Allergien
Preservatives, (Needs preservative-free ophthalmic preparations)
Vorherige Impfungen
Anthrax (Per military vaccination history self reported)

VAERS 2490898

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UJ768AC

gering
Staat
MI
Alter
67,0
Geschlecht
M
Eingang
27.10.2022
Impfdatum
19.10.2022
Beginn
19.10.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
OT / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Expired product administered Medication error No adverse event

Symptomtext

was given an expired FLUZONE HD QIV with no adverse event; Initial information received on 19-Oct-2022 regarding an unsolicited valid non-serious case received from a pharmacist. This case involves a 67 years old male patient who experienced was given an expired fluzone hd qiv with no adverse event while receiving vaccine INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT]. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included COVID-19 VACCINE (COVID-19 VACCINE) for Immunisation. On 19-Oct-2022, the patient received a 0.7 ml dose of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE (lot UJ768AC; expiry date: 30-Jun-2022) via intramuscular route in the deltoid NOS for immunization. On 19-OCT-2022 the patient developed a non-serious event was given an expired fluzone hd qiv with no adverse event (expired product administered) following the administration of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE. Action taken: not applicable. At time of reporting, the outcome was Unknown for the event. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
COVID-19 VACCINE
Allergien
-
Vorherige Impfungen
-

VAERS 2165192

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UJ768AC

gering
Staat
MN
Alter
74,0
Geschlecht
U
Eingang
16.02.2022
Impfdatum
12.10.2021
Beginn
-
Tage bis Beginn
-
Dosis
UNK
Route/Site
IM / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Joint range of motion decreased Magnetic resonance imaging Peripheral swelling Ultrasound scan

Symptomtext

decreased range of motion, swelling in arm - Do not know time of course of Sx - Patient received medrol pak & PT for Tx

Weitere VAERSDATA-Felder
Praegender Schweregrund
Joint range of motion decreased
Hospital-Tage
-
Labordaten
MRI, utrasound
Aktuelle Erkrankungen
NA
Vorgeschichte
NA
Andere Medikamente
NA
Allergien
-
Vorherige Impfungen
-

VAERS 2109241

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UJ768AC

gering
Staat
KS
Alter
40,0
Geschlecht
F
Eingang
12.02.2022
Impfdatum
27.01.2022
Beginn
27.01.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
OT / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Exposure during pregnancy No adverse event Product administered to patient of inappropriate age

Symptomtext

nurse gave a 40 year old pregnant patient an injection of FLUZONE HIGH DOSE QUADRIVALENT with no reported adverse event; nurse gave a 40 year old pregnant patient an injection of FLUZONE HIGH DOSE QUADRIVALENT with no reported adverse event; Initial information received on 27-Jan-2022 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 40 years old female patient who was exposed to vaccine INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT] in context of nurse gave a 40 year old pregnant patient an injection of fluzone high dose quadrivalent with no reported adverse event .Data regarding this pregnancy were received prospectively, i.e. before pregnancy outcome was known. The patient was 31 weeks pregnant. The date of last menstrual period was not reported. The estimated due date was not reported. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. The patient had unknown previous pregnancy/ies. On 27-Jan-2022, the patient received a dose of 0.7 ml of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE, injection ( strength: unknown) lot UJ768AC via intramuscular route in unknown administration site as Immunisation. On 27-JAN-2022 the patient developed a non-serious event "nurse gave a 40 year old pregnant patient an injection of fluzone high dose quadrivalent with no reported adverse event" (product administered to patient of inappropriate age) same day following the administration of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE. On 27-JAN-2022 the patient developed a non-serious event "nurse gave a 40 year old pregnant patient an injection of fluzone high dose quadrivalent with no reported adverse event" (exposure during pregnancy) same day following the administration of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE. Action taken was not applicable. It was not reported if the patient received a corrective treatment for the events (nurse gave a 40 year old pregnant patient an injection of FLUZONE HIGH DOSE QUADRIVALENT with no reported adverse event) At time of reporting, the outcome was Unknown for the event nurse gave a 40 year old pregnant patient an injection of fluzone high dose quadrivalent with no reported adverse event. Additionally, at time of reporting, the outcome of the pregnancy is unknown. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Exposure during pregnancy
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1840523

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UJ768AC

gering
Staat
ID
Alter
47,0
Geschlecht
F
Eingang
03.11.2021
Impfdatum
28.10.2021
Beginn
28.10.2021
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
No adverse event Product administered to patient of inappropriate age Wrong product administered

Symptomtext

No adverse reaction; patient received the incorrect vaccination, as she should have received Fluzone Quad not High Dose

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
None
Aktuelle Erkrankungen
NA
Vorgeschichte
NA
Andere Medikamente
Unknown
Allergien
No
Vorherige Impfungen
-

VAERS 1813076

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UJ768AC

gering
Staat
GA
Alter
-
Geschlecht
F
Eingang
23.10.2021
Impfdatum
-
Beginn
-
Tage bis Beginn
-
Dosis
UNK
Route/Site
OT / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Product storage error

Symptomtext

staff member noticed that it looked slightly frozen with no reported adverse event; Initial information was received on 14-Oct-2021 regarding an unsolicited valid non-serious case received via a nurse via Agency, Inquiry Number: 00812622). This case was considered as valid case due to patient involvement. This case involves an unknown age female patient who experienced was administered slightly frozen INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT] with no reported adverse event (product storage error). The patient's medical history, past medical treatments, concomitant medications, vaccinations and family history were not provided. On an unknown date, the patient received a 0.7ml dose of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE (lot number: UJ768AC and expiry date: 30-Jun-2022 via intramuscular route in the deltoid for prophylactic vaccination. It was reported "Nurse states that one of their staff members took home FLUZONE HIGH DOSE to administer to their mother, states the FLUZONE HIGH DOSE was placed directly on an ice pack in a Styrofoam cooler, states she is unable to report an exact temperature for temperature excursion because there was no temperature tag in the cooler; states it was there for 15-20 minutes. Nurse states when staff member took out the FLUZONE HIGH DOSE to administer, staff member noticed that it looked slightly frozen. Staff member thawed product by placing it against her skin then administered the product to her mother. Nurse states she thinks it was given 07OCT2021. Nurse does not know if it was the right or left deltoid Nurse asks if the product that was administered was still viable for use since it had appeared frozen, asks if the staff member's mother should be re-vaccinated. Agent provided nurse with stability data per Stability and Storage document, informed nurse we are unable to provide accurate suitability without a worst-case scenario temperature, agent informed nurse, per Stability and Storage document, vaccine should be discarded if it has been frozen. nurse states patient did not receive any treatment after receiving FLUZONE HIGH DOSE.nurse states patient was not pregnant at time of FLUZONE HIGH DOSE administration." At the time of reporting, no adverse event was reported. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product storage error
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1804698

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UJ768AC

gering
Staat
IA
Alter
81,0
Geschlecht
F
Eingang
21.10.2021
Impfdatum
19.10.2021
Beginn
19.10.2021
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Extra dose administered No adverse event Wrong product administered

Symptomtext

Resident had completed Pfizer Covid 2 dose series plus 1 booster dose (Dates: 1/15/21; 02/15/21; 09/28/21). At clinic to receive a influenza vaccine. Vaccinator administered an additional Pfizer Covid in error. This would represent a 4th dose. Error realized. Patient notified. Correct vaccine (influenza High dose) was administered. Follow up with patient the next day. No adverse reactions.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Extra dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
Lupus Diverticulitis
Andere Medikamente
unknown
Allergien
unknown
Vorherige Impfungen
-